Abstract
Vesicular monoamine transporters (VMATs) are involved in the presynaptic packaging of monoaminergic neurotransmitters into storage granules. Upon an action potential, vesicles release their contents into the synaptic cleft via exocytosis. Since insufficient or excess release of neurotransmitter might alter neurochemical function and neurotransmission, VMATs are an important target for biological research in neuropsychiatric disorders. Two structurally related but pharmacologically distinct VMATs have been identified, encoded by separate genes, VMAT1 (SLC18A1) and VMAT2 (SLC18A2). Although it was reported initially that only VMAT2 is expressed in brain, recent studies indicate that VMAT1 is also expressed in brain, thus making both transporters plausible candidate genes for neuropsychiatric disorders. The gene encoding VMAT1 is located on chromosome 8p21, a region implicated in linkage studies of schizophrenia, bipolar disorder, and anxiety-related phenotypes. Furthermore, several recent genetic case–control studies have documented an association between common missense variations in the VMAT1 gene and susceptibility to bipolar disorder and schizophrenia. Variations in the VMAT1 gene might affect transporter function and might be involved in the etiology of neuropsychiatric disorders. This chapter describes methods for genotyping three missense polymorphisms implicated in neuropsychiatric disorders (Thr4Pro, Thr98Ser, Thr136Ile) using TaqMan-based PCR and standard PCR approaches.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Liu, Y., Peter, D., Roghani, A., Schuldiner, S., Prive, G.G., Eisenberg, D., Brecha, N., and Edwards, R.H. (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70, 539–551.
Peter, D., Finn, J.P., Klisak, I., Liu, Y., Kojis, T., Heinzmann, C., Roghani, A., Sparkes, R.S., and Edwards, R.H. (1993) Chromosomal localization of the human vesicular amine transporter genes. Genomics 18, 720–723.
Erickson, J.D., Schafer, M.K., Bonner, T.I., Eiden, L.E., and Weihe, E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. U S A 93, 5166–5171.
Eiden, L.E., Schafer, M.K., Weihe, E., and Schutz, B. (2004) The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch. 447, 636–640.
Hansson, S.R., Hoffman, B.J., and Mezey, E. (1998) Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Brain Res. Dev. Brain Res. 110, 135–158.
Lohoff, F.W., Dahl, J.P., Ferraro, T.N., Arnold, S.E., Gallinat, J., Sander, T., and Berrettini, W.H. (2006) Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder. Neuropsychopharmacology 31, 2739–2747.
Brunk, I., Blex, C., Rachakonda, S., Holtje, M., Winter, S., Pahner, I., Walther, D.J., and Ahnert-Hilger, G. (2006) The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J. Biol. Chem. 281, 33373–33385.
Chen, F.E. and Huang, J. (2005) Reserpine: a challenge for total synthesis of natural products. Chem. Rev. 105, 4671–4706.
Schildkraut, J.J. and Kety, S.S. (1967) Biogenic amines and emotion. Science 156, 21–37.
Heslop, K.E. and Curzon, G. (1999) Effect of reserpine on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology 38, 883–891.
Goodwin, F.K. and Bunney, W.E., Jr. (1971) Depressions following reserpine: a reevaluation. Semin. Psychiatry 3, 435–448.
Bant, W.P. (1978) Antihypertensive drugs and depression: a reappraisal. Psychol. Med. 8, 275–283.
Widmer, R.B. (1985) Reserpine: the maligned antihypertensive drug. J. Fam. Pract. 20, 81–83.
Baumeister, A.A., Hawkins, M.F., and Uzelac, S.M. (2003) The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 12, 207–220.
Berger, S.P., Winhusen, T.M., Somoza, E.C., Harrer, J.M., Mezinskis, J.P., Leiderman, D.B., Montgomery, M.A., Goldsmith, R.J., Bloch, D.A., Singal, B.M., and Elkashef, A. (2005) A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 100 (Suppl 1), 58–67.
Winhusen, T., Somoza, E., Sarid-Segal, O., Goldsmith, R.J., Harrer, J.M., Coleman, F.S., Kahn, R., Osman, S., Mezinskis, J., Li, S.H., Lewis, D., Afshar, M., Ciraulo, D.A., Horn, P., Montgomery, M.A., and Elkashef, A. (2007) A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence. Drug Alcohol Depend. 91, 205–212.
Leiderman, D.B., Shoptaw, S., Montgomery, A., Bloch, D.A., Elkashef, A., LoCastro, J., and Vocci, F. (2005) Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 100 (Suppl 1), 1–11.
Hayden, M.R., Leavitt, B.R., Yasothan, U., and Kirkpatrick, P. (2009) Tetrabenazine. Nature Rev. 8, 17–18.
Kenney, C., and Jankovic, J. (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert. Rev. Neurother. 6, 7–17.
Cordeiro, M.L., Gundersen, C.B., and Umbach, J.A. (2002) Lithium ions modulate the expression of VMAT2 in rat brain. Brain Res. 953, 189–194.
Cordeiro, M.L., Gundersen, C.B., and Umbach, J.A. (2004) Convergent effects of lithium and valproate on the expression of proteins associated with large dense core vesicles in NGF-differentiated PC12 cells. Neuropsychopharmacology 29, 39–44.
Cordeiro, M.L., Umbach, J.A., and Gundersen, C.B. (2000) Lithium ions Up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cells. J Neurochem 75, 2622–2625.
Manji, H.K. and Lenox, R.H. (2000) Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol. Psychiatry 48, 518–530.
Tamminga, C.A. and Holcomb, H.H. (2005) Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10, 27–39.
Zheng, G., Dwoskin, L.P., and Crooks, P.A. (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. Aaps J. 8, E682–692.
Zubieta, J.K., Huguelet, P., Ohl, L.E., Koeppe, R.A., Kilbourn, M.R., Carr, J.M., Giordani, B.J., and Frey, K.A. (2000) High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am. J. Psychiatry 157, 1619–1628.
Zubieta, J.K., Taylor, S.F., Huguelet, P., Koeppe, R.A., Kilbourn, M.R., and Frey, K.A. (2001) Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol. Psychiatry 49, 110–116.
Lin, Z., Walther, D., Yu, X.-Y., Li, S., Drgon, T., and Uhl, G.R. (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum. Mol. Genet. 14, 1393–1404.
Little, K.Y., Krolewski, D.M., Zhang, L., and Cassin, B.J. (2003) Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am. J. Psychiatry 160, 47–55.
Wilson, J.M., Levey, A.I., Bergeron, C., Kalasinsky, K., Ang, L., Peretti, F., Adams, V.I., Smialek, J., Anderson, W.R., Shannak, K., Deck, J., Niznik, H.B., and Kish, S.J. (1996) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40, 428–439.
DaSilva, J.N., Kilbourn, M.R., and Mangner, T.J. (1993) Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter. Appl. Radiat. Isot. 44, 1487–1489.
DaSilva, J.N., Carey, J.E., Sherman, P.S., Pisani, T.J., and Kilbourn, M.R. (1994) Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl. Med. Biol. 21, 151–156.
Lohoff, F.W., Lautenschlager, M., Mohr, J., Ferraro, T.N., Sander, T., and Gallinat, J. (2008) Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits. Neurosci. Lett. 434, 41–45.
Lohoff, F.W., Weller, A.E., Bloch, P.J., Buono, R.J., Doyle, G.A., Ferraro, T.N., and Berrettini, W.H. (2008) Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology 57, 55–60.
Roghani, A., Welch, C., Xia, Y., Liu, Y., Peter, D., Finn, J.P., Edwards, R.H., and Lusis, A.J. (1996) Assignment of the mouse vesicular monoamine transporter genes, Slc18a1 and Slc18a2, to chromosomes 8 and 19 by linkage analysis. Mamm. Genome 7, 393–394.
Berrettini, W. (2003) Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am. J. Med. Genet. 123C, 59–64.
Berrettini, W. (2004) Bipolar disorder and schizophrenia: convergent molecular data. Neuromolecular Med. 5, 109–117.
Park, N., Juo, S.H., Cheng, R., Liu, J., Loth, J.E., Lilliston, B., Nee, J., Grunn, A., Kanyas, K., Lerer, B., Endicott, J., Gilliam, T.C., and Baron, M. (2004) Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol. Psychiatry 9, 1091–1099.
Cheng, R., Juo, S.H., Loth, J.E., Nee, J., Iossifov, I., Blumenthal, R., Sharpe, L., Kanyas, K., Lerer, B., Lilliston, B., Smith, M., Trautman, K., Gilliam, T.C., Endicott, J., and Baron, M. (2006) Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry 11, 252–260.
Craddock, N. and Jones, I. (1999) Genetics of bipolar disorder. J. Med. Genet. 36, 585–594.
Smoller, J.W. and Finn, C.T. (2003) Family, twin, and adoption studies of bipolar disorder. Am. J. Med. Genet. C. Semin. Med. Genet. 123, 48–58.
Moller, H.J. (2003) Bipolar disorder and schizophrenia: distinct illnesses or a continuum? J. Clin. Psychiatry 64 (Suppl 6), 23–27; discussion 28.
Sikich, L. (2008) Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J. Clin. Psychiatry 69 (Suppl 4), 21–25.
Bly, M. (2005) Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia. Schizophr. Res. 78, 337–338.
Richards, M., Iijima, Y., Kondo, H., Shizuno, T., Hori, H., Arima, K., Saitoh, O., and Kunugi, H. (2006) Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav. Brain Funct. 2, 39.
Chen, S.F., Chen, C.H., Chen, J.Y., Wang, Y.C., Lai, I.C., Liou, Y.J., and Liao, D.L. (2007) Support for association of the A277C single nucleotide polymorphism in human vesicular monoamine transporter 1 gene with schizophrenia. Schizophr. Res. 90, 363–365.
Sievert, M.K., and Ruoho, A.E. (1997) Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J. Biol. Chem. 272, 26049–26055.
Senkowski, D., Linden, M., Zubragel, D., Bar, T., and Gallinat, J. (2003) Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol. Psychiatry 53, 304–314.
Charney, D.S. and Deutch, A. (1996) A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10, 419–446.
Handley, S.L. (1995) 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. & Ther. 66, 103–148.
Acknowledgments
This work was supported by the Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania. Financial support is gratefully acknowledged from National Institutes of Health grant K08MH080372. The author would like to thank Thomas Ferraro, Glenn Doyle, and Paul Bloch for their very helpful comments, suggestions, improvements, and corrections.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lohoff, F.W. (2010). Genetic Variants in the Vesicular Monoamine Transporter 1 (VMAT1/SLC18A1) and Neuropsychiatric Disorders. In: Yan, Q. (eds) Membrane Transporters in Drug Discovery and Development. Methods in Molecular Biology, vol 637. Humana Press. https://doi.org/10.1007/978-1-60761-700-6_9
Download citation
DOI: https://doi.org/10.1007/978-1-60761-700-6_9
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-699-3
Online ISBN: 978-1-60761-700-6
eBook Packages: Springer Protocols